Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CytImmune Sciences
AddedFeb 15, 2024
UpdatedJun 18, 2026
CytImmune Sciences

CytImmune Sciences

Acquired

CytImmune Sciences develops patented nanomedicines that target and destroy tumor blood vessels, enhancing the effectiveness of other therapies.

HQ
Rockville, MD, US
Founded
1988
Overview
Compare
Fundraising
Employees
Website

Founded in Rockville, United States, CytImmune Sciences is a biotechnology company dedicated to developing patented nanomedicines aimed at targeting and destroying tumor blood vessels. Their core mission is to enhance the effectiveness of existing cancer therapies such as chemotherapies, radiation therapies, and immunotherapies through their innovative platform, Aurimune™. The company's flagship product, CYT-6091, represents a first-in-class therapeutic designed to alter the tumor microenvironment for improved treatment outcomes.

CytImmune Sciences has recently sold its technology to Zahav Bioscience LLC, marking a significant milestone in its journey. The company's pioneering work in nanomedicine has garnered attention from notable investors and industry leaders. With a phase II ready biotechnology platform, CytImmune has made substantial strides in cancer treatment, positioning itself as a key player in the oncology sector. Their impact lies in potentially transforming the therapeutic landscape for solid tumors through advanced combination therapies.

CytImmune Sciences - Similar Companies

OmniCyte logo

OmniCyte

omnicyte.com

CytoAgents logo

CytoAgents

cytoagents.com

CytoLogic logo

CytoLogic

Immunome logo

Immunome

Imunon logo

Imunon

imunon.com

Cello Therapeutics logo

Cello Therapeutics

cellothera.com

CytomX Therapeutics logo

CytomX Therapeutics

cytomx.com

ImmuneBridge logo

ImmuneBridge

immunebridge.com

CytoSite Biopharma logo

CytoSite Biopharma

INmune Bio logo

INmune Bio

inmunebio.com

Cel-Sci logo

Cel-Sci

cel-sci.com

ImmuCision Biotherapeutics logo

ImmuCision Biotherapeutics

AffyImmune Therapeutics logo

AffyImmune Therapeutics

affyimmune.com

ImmunoGenesis logo

ImmunoGenesis

immunogenesis.com

ImmunGene logo

ImmunGene

CytImmune Sciences - Quick Facts

Who are CytImmune Sciences' competitors?

Companies similar to CytImmune Sciences include OmniCyte, CytoAgents, CytoLogic and Immunome.

When was CytImmune Sciences founded?

CytImmune Sciences was founded in 1988.

Where is CytImmune Sciences' headquarters located?

CytImmune Sciences' headquarters is located in Rockville, MD, US.

How much has CytImmune Sciences raised to-date?

As of Dec 28, 2020, CytImmune Sciences has raised a total of $11.1M (USD).

CytImmune Sciences - Classification

Ownership
  • Private
Technology
  • Nanotechnology
Geographic Exposure
  • Americas
Customer
  • Enterprise
Main Product
  • Cancer Therapies
  • Nanomedicines
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified